Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Indivior Pharmaceuticals IncNASDAQ: INDV

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 129M shares rose 4.3% year over year, ahead of the +0.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -2.7% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.3% holds above the trailing-twelve-month pace of +0.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
129M+0.0% QoQ
Last fiscal yearDec 2025
128M-3.8% YoY
LTMJun 2026
128M+0.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%——
1 year-3.8%——
3-year CAGR-2.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
128M USD
Year-over-year change
-3.8%
4-year CAGR
-4.6%

Weighted Avg Shares (Diluted) vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 weighted avg shares (diluted) of 128M shares is the 2nd highest of the 4 companies compared; the peer median is 57.4M shares.
  • Its year-over-year change of +0.6% is the lowest of 4, against a peer median of +2.1%.
  • Over three fiscal years its annual growth of -2.7% compares with a peer median of +1.0%.
INDV Competitors Peer median
Weighted Avg Shares (Diluted) for INDV and competitors
Company Period LTM YoY 3-year CAGR
ALKSAlkermes plcLTM Sep 2026169.48M +0.9%+1.0%
INDVIndivior Pharmaceuticals IncLTM Jun 2026128M +0.6%-2.7%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.4M +2.1%-2.9%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202639.57M +3.1%+5.5%
Peer median (excluding INDV) 57.4M+2.1%+1.0%

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue791M901M1.09B1.19B1.24B
Cost of Revenue127M151M174M231M246M
Gross Profit664M750M919M957M993M
Gross Margin83.9%83.2%84.1%80.6%80.1%
Research & Development52M74M116M107M97M
Selling, General & Admin431M469M569M618M634M
Operating Expenses451M831M1.08B925M728M
Depreciation & Amortization22M16M15M28M20M
EBITDA238M(46M)(99M)83M304M
EBITDA Margin30.1%-5.1%-9.1%7.0%24.5%
Operating Income213M(81M)(156M)32M265M
Operating Margin26.9%-9.0%-14.3%2.7%21.4%
Interest Income4M19M43M23M22M
Interest Expense26M29M35M41M45M
Other Income / Expenses(23M)(8M)7M(18M)(26M)
Income Before Tax190M(89M)(149M)14M239M
Pre-Tax Margin24.0%-9.9%-13.6%1.2%19.3%
Income Tax Expense(15M)(44M)(20M)11M29M
Net Income205M(44M)(129M)2M210M
Net Margin25.9%-4.9%-11.8%0.2%16.9%
EPS (Basic)1.38(0.37)(0.94)0.021.68
EPS (Diluted)1.31(0.37)(0.91)0.021.64
Weighted Avg Shares145.66M139.01M137.31M132M125M
Weighted Avg Shares (Diluted)154.23M139.01M141.8M133M128M

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.